ð ãã®èšäºã¯å»çæ
å ±ãå«ã¿ãŸããGLP-1è¬ã¯èªç±èšºçã§ãã广ã»å¯äœçšã«ã¯å人差ããããŸããå¿
ãå»åž«ã®èšºå¯ãåããŠãã ããã
ð¡ æçµæŽæ°: 2026幎4æïœæéã¯åã¯ãªããã¯å
¬åŒãµã€ãããåŒçš
- ãã®èšäºãèªãã°ãããããš
- ãçµè«ããã³ãžã£ããå®ããªã³ã©ã€ã³èšºçããããã©ã³ãã³ã°
- åã¯ãªããã¯ã®è©³çްæ¯èŒ
- ð¥ 第1äœ: Actually,ïŒã¢ã¯ãã¥ã¢ãªãŒïŒ
- ð¥ 第2äœ: ã¬ãã¯ãª
- ãªã³ã©ã€ã³èšºçã®æµãïŒãã£ã4ã¹ãããïŒ
- ãã³ãžã£ãã®å¹æïŒ72é±éã§å¹³å21.4%ã®äœéæžå°
- ãã³ãžã£ãã®å¯äœçšãšå¯Ÿç
- ãããã質åïŒFAQïŒ
- ãŸãšãïŒããªãã«åã£ãã¯ãªããã¯ã®éžã³æ¹
- åèæç®
ãã®èšäºãèªãã°ãããããš
- ãã³ãžã£ããæãå®ãã¯ãªããã¯ã¯ã©ããïŒ2026幎4æææ°æéïŒ
- è¬ä»£ã ãã§ãªãèšºå¯æã»éæèŸŒã¿ã®ç·é¡ã§æ¯èŒããçµæ
- åå5,000åOFFã«ãªãã¯ãŒãã³æ å ±
- ãã³ãžã£ãã®å¹æã»å¯äœçšã»æ³šæç¹
- ãªã³ã©ã€ã³èšºçã®å ·äœçãªæµãïŒäºçŽãå±ããŸã§ïŒ
- å®éã«äœ¿ã£ã人ã®å£ã³ãã»äœéšè«
ãçµè«ããã³ãžã£ããå®ããªã³ã©ã€ã³èšºçããããã©ã³ãã³ã°
ð ããªãã«æé©ãªGLP-1è¬ã30ç§ã§èšºæ
6ã€ã®è³ªåã«çããã ãã§ãäœè³ªã»äºç®ã«åã£ãè¬ãšã¯ãªããã¯ãããããŸã
ç¡æAI蚺æãåãã â
⻠蚺æã¯ç¡æã»ç»é²äžèŠã§ã
15瀟ã調æ»ããçµæãç·é¡ïŒè¬ä»£ïŒèšºå¯æïŒéæïŒã§æ¯èŒãããšä»¥äžã®é çªã«ãªããŸããã
ð° ãã³ãžã£ã2.5mg æé¡ç·é¡æ¯èŒïŒ2026幎4æïŒ
åã¯ãªããã¯ã®è©³çްæ¯èŒ
| ã¯ãªãã㯠| ãã³ãžã£ã2.5mg | èšºå¯æ | éæ | ç·é¡/æ | ååå²åŒ |
|---|---|---|---|---|---|
| Actually, | Â¥12,380~ | åèšºç¡æ | Â¥550 | Â¥12,930 | – |
| ã¯ãªããã¯ãã©ã¢ | Â¥20,520~ | å®è³ªç¡æ | Â¥1,100 | Â¥21,620 | 5,000åOFF |
| DMMãªã³ã©ã€ã³ | Â¥22,000~ | ç¡æ | Â¥550 | Â¥22,550 | 5,000åOFF |
| ã€ãŒã¹ãé§ å | Â¥21,100~ | ç¡æ | Â¥1,100 | Â¥22,200 | LINE2,000åOFF |
| ã¬ãã¯ãª | Â¥26,433~ | ç¡æ | Â¥550 | Â¥26,983 | – |
ð¥ 第1äœ: Actually,ïŒã¢ã¯ãã¥ã¢ãªãŒïŒ
ããšã«ããå®ããã³ãžã£ããå§ããã人ãã«æé©
Actually,ã¯åœå æå®å€æ°Žæºã§ãã³ãžã£ããåŠæ¹ãããªã³ã©ã€ã³èšºçãµãŒãã¹ã§ãã6ã¶æåãŸãšãè²·ããªãæé¡Â¥12,380~ãšããæ¥çæå®å€ã§ãä»ã¯ãªããã¯ãšæ¯ã¹ãŠçŽ1äžåãå®ãäŸ¡æ Œèšå®ã§ãã
Actually,ã®3ã€ã®åŒ·ã¿
- åœå æå®å€: ãã³ãžã£ã2.5mgæé¡Â¥12,380~ã¯æ¥çæå®
- æçç¿æ¥çºé: 蚺å¯åŸããã«èªå® ã«å±ã
- ãã©ã€ãã·ãŒé æ ®: ã¯ãªããã¯åãåãããªã梱å ã§å±ã
Actually,ã®ãã¡ãªãã
- 6ã¶æãŸãšãè²·ããæå®ãªã®ã§ãåæè²»çšãé«ã
- 察é¢èšºçã«ã¯é察å¿
Actually,ã¯ãããªäººã«ãããã
- â æé¡è²»çšããšã«ããæããã人
- â 3ã¶æä»¥äžã®ç¶ç¶ãèããŠãã人
- â ãªã³ã©ã€ã³èšºçã«æµæããªã人
ð¥ Actually, å ¬åŒãµã€ã
å蚺æç¡æã»æçç¿æ¥çºé
ð¥ 第2äœ: ã¬ãã¯ãª
ã顧客æºè¶³åºŠ95%ã®å®å¿æã§éžã³ãã人ãã«æé©
ã¬ãã¯ãªã¯ã¬ãã¬ãžãŒãºæ ªåŒäŒç€Ÿãéå¶ãããªã³ã©ã€ã³èšºçãµãŒãã¹ã§ãã24æé365æ¥äºçŽå¯èœã§ãæç30ååŸã«èšºçéå§ã顧客æºè¶³åºŠ95%ãšããé«ãè©äŸ¡ãåŸãŠããŸãã
ã¬ãã¯ãªã®3ã€ã®åŒ·ã¿
- 24æé365æ¥äºçŽOK: æ·±å€ã»æ©æã§ãäºçŽå¯èœ
- æç30ååŸã«èšºç: æãç«ã£ããããå蚺
- ãªãã«ãµã¹æÂ¥5,820~: å æè¬ãå®ã
ð¥ ã¬ãã¯ãª å ¬åŒãµã€ã
èšºå¯æç¡æã»24æéäºçŽå¯èœ
ãªã³ã©ã€ã³èšºçã®æµãïŒãã£ã4ã¹ãããïŒ
ãã³ãžã£ãã®å¹æïŒ72é±éã§å¹³å21.4%ã®äœéæžå°
ãã³ãžã£ãïŒãã«ãŒãããïŒã¯ãGIP/GLP-1å容äœäœåè¬ã§ããåŸæ¥ã®GLP-1è¬ïŒãªãã«ãµã¹ããªãŒã³ããã¯ïŒãšç°ãªããGIPãšGLP-1ã®äºéäœçšã«ãããããé«ã广ãæåŸ ã§ããŸãã
ð èšåºè©Šéšã®çµæïŒSURMOUNT-1ïŒ
ãã³ãžã£ãã®å¯äœçšãšå¯Ÿç
| å¯äœçš | é »åºŠ | 察ç |
|---|---|---|
| åãæ° | æãå€ã | å°éããéå§ããåŸã ã«å¢éãé£äºãå°éã〠|
| äžç¢ | ããå€ã | æ°Žåãååã«æåãèã£ããé£äºãé¿ãã |
| äŸ¿ç§ | æã | é£ç©ç¹ç¶ãšæ°Žåãæèãé©åºŠãªéå |
| 泚å°éšäœã®åå¿ | ãŸã | 泚å°éšäœãããŒããŒã·ã§ã³ |
â ïž å€ãã®å¯äœçšã¯æ°é±éã§è»œæžããŸãã匷ãçç¶ãç¶ãå Žåã¯å»åž«ã«çžè«ããŠãã ããã
ãããã質åïŒFAQïŒ
Q. ãã³ãžã£ãã¯æ¬åœã«éåãªãã§ç©ããŸããïŒ
ã¯ããGLP-1/GIPå容äœã«äœçšãã飿¬²ãèªç¶ã«æå¶ãããããç¡çãªéåãé£äºå¶éãªãã§ãäœéæžå°ãæåŸ ã§ããŸãããã ããé©åºŠãªéåã䜵çšãããšããã«å¹æçã§ãã
Q. ãªã³ã©ã€ã³èšºçã¯å®å šã§ããïŒ
ã¯ããäžèšã¯ãªããã¯ã¯å šãŠæ£èŠã®å»çæ©é¢ã§ããåŠæ¹ãããè¬ãåœå æ£èŠåã®ã¿ãåäººèŒžå ¥ãšç°ãªããå質ãä¿èšŒãããŠããŸãã
Q. ãã³ãžã£ãã¯ãã€ãã广ãåºãŸããïŒ
å人差ã¯ãããŸãããäžè¬çã«2-4é±éã§é£æ¬²æå¶å¹æã宿ãã1-3ã¶æã§äœéæžå°ãç®ã«èŠããŠããŸãã
Q. ãã³ãžã£ãããããããªããŠã³ãããŸããïŒ
æ¥ã«ããããšé£æ¬²ãæ»ãããªããŠã³ãããå¯èœæ§ããããŸããå»åž«ãšçžè«ããªããåŸã ã«æžéããçæŽ»ç¿æ £ã®æ¹åãšäœµçšããããšã倧åã§ãã
Q. ä¿éºã¯é©çšãããŸããïŒ
ãã€ãšããç®çã®å Žåã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ãã2åç³å°¿ç ã®æ²»çç®çã§ããã°ä¿éºé©çšã«ãªããŸãã
ãŸãšãïŒããªãã«åã£ãã¯ãªããã¯ã®éžã³æ¹
â ãšã«ããå®ãããã â Actually,ïŒæÂ¥12,380~ã§æ¥çæå®ïŒ
â å®å¿æãšå®çžŸéèŠ â DMMãªã³ã©ã€ã³ïŒ200äžä»¶+ã®å®çžŸïŒ
â ä»ããå§ããã â ã¬ãã¯ãªïŒ24æéäºçŽã»æç30åã§èšºå¯ïŒ
â 察é¢ã§ãçžè«ããã â ã¯ãªããã¯ãã©ã¢ïŒå šåœ13é¢+ãªã³ã©ã€ã³ïŒ
åèæç®
- Eli Lilly and Company “SURMOUNT-1: Tirzepatide Phase 3 Clinical Trial”
- æ¥æ¬è¥æºåŠäŒãè¥æºç蚺çã¬ã€ãã©ã€ã³2022ã
- åçåŽåçãå»çåºåã¬ã€ãã©ã€ã³ã
- å»è¬åå»çæ©åšç·åæ©æ§ïŒPMDAïŒå»è¬åæ å ±
â ïž éèŠäºé
ã»æ¬èšäºã§ç޹ä»ããŠããGLP-1è¬ã¯ãã€ãšããç®çã§ã®äœ¿çšã¯èªç±èšºçïŒä¿éºé©çšå€ïŒã§ã
ã»å¹æã»å¯äœçšã«ã¯å人差ããããŸã
ã»å¿
ãå»åž«ã®èšºå¯ãåããæç€ºã«åŸã£ãŠäœ¿çšããŠãã ãã
ã»å人茞å
¥ã¯å質ãä¿èšŒãããå±éºã§ããå¿
ãæ£èŠã®å»çæ©é¢ã§åŠæ¹ãåããŠãã ãã
ã»æéã¯2026幎4ææç¹ã®æ
å ±ã§ããææ°ã®æéã¯åã¯ãªããã¯å
¬åŒãµã€ããã確èªãã ãã
ð ãã£ãšè©³ããç¥ãããæ¹ãž
âââââ AIèšºææºè¶³åºŠ96%
ããªãã«æé©ãªGLP-1ãã€ãšãããèŠã€ããŸãããïŒ6ã€ã®è³ªåã«çããã ãã§ãããªãã«ããã¿ãªã®è¬ã»ã¯ãªããã¯ãææ¡ããŸãã
â ïž éèŠãªãç¥ããïŒGLP-1ãã€ãšããã«ã€ããŠïŒ
- æªæ¿èªå»è¬åã§ããããšã®æç€º
- ãªãã«ãµã¹ããã³ãžã£ãããªãŒã³ããã¯ããµã¯ã»ã³ãã¯2åç³å°¿ç ã®å¹èœã»å¹æã§æ¿èªãããŠããŸããããã€ãšããç®çã®äœ¿çšã¯åœå ã§æ¿èªãããŠããŸããã
- å¯äœçšè¢«å®³ææžå¶åºŠ
- é©å¿å€äœ¿çšã®è¬å€ã«ããå¯äœçšã¯ãå»è¬åå¯äœçšè¢«å®³ææžå¶åºŠãã®å¯Ÿè±¡å€ã§ãã
- åºåã«ã€ããŠ
- åœãµã€ãã¯ã¢ãã£ãªãšã€ãåºåãå©çšããŠããŸããã©ã³ãã³ã°ã»è©äŸ¡ãžã®åœ±é¿ã¯ãããŸããã


ã³ã¡ã³ã